Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biofrontera expands patent protection for migraine prophylaxis drug
The patents protect the use of this substance as a pharmaceutical product in these countries. The two patents granted now expand the scope of protection for BF-1, which
The patents protect the use of this substance as a pharmaceutical product in these countries. The two patents granted now expand the scope of protection for BF-1, which
In the past five years, the company has experienced a 150% increase in employees at its US headquarters. The new building will have the capacity for more than
The trial is an open-label, randomized, single-dose, cross-over study investigating the pharmacokinetics and safety of three different extended release formulations of a well-known opioid product compared to the
Mark Parry-Billings, chief development officer, and Lisa Nolan, senior vice president, Business Development, remain in their leadership roles and will work closely with company’s board of directors to
Evotec will support InterMune’s research efforts using their medicinal chemistry know-how. In addition, they will utilize their expertise and technologies in computational chemistry, protein production, X-Ray crystallography and
The Singapore-based team will consist initially of marketing managers, application specialists and field service engineers supporting BioMerieux distributors in the ASEAN (The Association of Southeast Asian Nations) countries,
Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad
This is claimed to be the largest single investment to date in chemicals R&D. Construction will begin in June 2008 and is expected to be completed by the
Andrew Bonfield, executive vice president and CFO, will remain in that role until Mr Huet’s arrival. He will leave the company after a period of transition to seek
High levels of FASN are present in most cancer types and are associated with diminished patient survival. Reduction of FASN activity has been reported to lead to cancer